Genomic analysis of 51 SCLC patient specimens has revealed that about 36% of the SCLC tumors harbor genetic alterations in the PI3K/AKT/mTOR pathway, including point mutations and copy number changes in AKT2, AKT3, PTEN, PIK3CA, RICTOR and MTOR [5]. This evidence concerns the gene MTOR and small cell lung carcinoma.